Haemolytic activities of plant saponins and adjuvants. Effect of Periandra mediterranea saponin on the humoral response to the FML antigen of Leishmania donovani.
An 87.7% (P < 0.01) and 84% (P < 0.001) of protection against visceral leishmaniasis was achieved in CB hamsters and Balb/c mice, respectively, with saponin combined to the fucose-mannose ligand of Leishmania donovani (FML). However, an undesirable haemolytic effect was described for several saponins. Aiming to improve the formulation with FML/saponin, we comparatively analysed the haemolytic potential of recently characterized plant saponins and currently used adjuvants. The haemolytic activity of steroidic saponins from Agave sisalana; Smilax officinalis as well as commercial saponin (Riedel De Haën's), was higher than that of triterpenoid ones (Bredemeyera floribunda; Periandra mediterranea) and the Freund's complete adjuvant. The concentration resulting in 50% haemolysis was 500 micrograms ml-1 for aluminum hydroxide. The low haemolytic effect of P. mediterranea saponin was abolished by removal of its glycidic moiety and its sapogenin fraction as well as the Freund's Incomplete Adjuvant were non-haemolytic within this range. Furthermore, the adjuvant effect of three doses of P. mediterranea saponin injected with the FML antigen of L. donovani, was assayed in mice, either by the intraperitoneal (i.p.) or the subcutaneous (s.c.) route. The anti-FML IgG antibody levels increased and detectable levels were observed up to 3 months in the s.c. group. The response was expanded in both groups after an injection with a fourth vaccine dose. The IgG response showed increased levels of IgG2a only in the i.p. group, while IgG2b and IgG1 but not IgG3 antibodies were higher than controls in both groups. In conclusion, the results suggest that the recently described triterpenoid fractions of P. mediterranea can be safely used as adjuvant with low or non-haemolytic effect.
Santos
W R
WR
Instituto de Microbiologia, Universidade Federal do Rio de Janeiro (UFRJ), CCS, Cidade Universitária, Brazil.
Bernardo
R R
RR
Peçanha
L M
LM
Palatnik
M
M
Parente
J P
JP
Palatnik de Sousa
C B
CB
D000276:Adjuvants, Immunologic / Q000633:toxicity*; D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D000953:Antigens, Protozoan / Q000276:immunology*; D006224:Cricetinae; D005643:Fucose / Q000276:immunology* / Q000378:metabolism; D006460:Hemolysin Proteins / Q000633:toxicity*; D006801:Humans; D037102:Lectins / Q000276:immunology* / Q000633:toxicity; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000517:prevention & control; D008024:Ligands; D008358:Mannose / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010936:Plant Extracts / Q000633:toxicity; D012503:Saponins / Q000276:immunology* / Q000633:toxicity
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D006460:Hemolysin Proteins; D037102:Lectins; D008024:Ligands; D010936:Plant Extracts; D012503:Saponins; C027112:fucose-binding lectin; D005643:Fucose; D008358:Mannose